Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2020

24.01.2020 | Original Article

Interleukin-35 Suppresses CD8+ T Cell Activity in Patients with Viral Hepatitis-Induced Acute-on-Chronic Liver Failure

verfasst von: Lanlan Yang, Qian Zhang, Jie Song, Wudong Wang, Zhenjing Jin

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Interleukin (IL)-35 is a newly indentified cytokine and induces immunotolerance via suppression of CD8+ T cell activity in chronic viral hepatitis.

Aims

To investigate the modulatory function of IL-35 to CD8+ T cells in viral hepatitis-induced acute-on-chronic liver failure (ACLF).

Methods

Fifty-five ACLF patients and 21 healthy controls were enrolled. Serum IL-35 concentration was measured by ELISA. Absolute accounts for T cells, immune checkpoint molecules, and cytotoxic molecules in CD8+ T cells were measured by flow cytometry and real-time PCR, respectively. Direct and indirect contact co-culture systems between CD8+ T cells and HepG2 cells were set up. The regulatory function of IL-35 to CD8+ T cells was assessed by measuring lactate dehydrogenase expression and cytokine production.

Results

Serum IL-35 concentration was elevated in ACLF patients and positively correlated with total bilirubin, but negatively correlated with prothrombin time activity. Peripheral CD8+ T cells showed exhausted phenotype in ACLF patients, which manifested as up-regulation of programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) but down-regulation of perforin, granzyme B, and FasL. Recombinant IL-35 stimulation dampened cytotoxicity and interferon-γ production in both direct and indirect contact co-culture systems. This process was accompanied by elevation of PD-1, CTLA-4, and LAG3, as well as reduction of perforin, granzyme B, and FasL in CD8+ T cells.

Conclusion

Elevated IL-35 suppressed both cytolytic and non-cytolytic activity of CD8+ T cells in ACLF patients.
Literatur
1.
Zurück zum Zitat Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. Lancet. 2015;386:1576–1587.CrossRef Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. Lancet. 2015;386:1576–1587.CrossRef
2.
Zurück zum Zitat Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.PubMed Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553.PubMed
3.
Zurück zum Zitat Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:1–38. Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:1–38.
4.
Zurück zum Zitat Arroyo V, Jalan R. Acute-on-Chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis. 2016;36:109–116.CrossRef Arroyo V, Jalan R. Acute-on-Chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis. 2016;36:109–116.CrossRef
5.
Zurück zum Zitat Blasco-Algora S, Masegosa-Ataz J, Gutierrez-Garcia ML, Alonso-Lopez S, Fernandez-Rodriguez CM. Acute-on-chronic liver failure: pathogenesis, prognostic factors and management. World J Gastroenterol. 2015;21:12125–12140.CrossRef Blasco-Algora S, Masegosa-Ataz J, Gutierrez-Garcia ML, Alonso-Lopez S, Fernandez-Rodriguez CM. Acute-on-chronic liver failure: pathogenesis, prognostic factors and management. World J Gastroenterol. 2015;21:12125–12140.CrossRef
6.
Zurück zum Zitat Hensley MK, Deng JC. Acute on chronic liver failure and immune dysfunction: a mimic of sepsis. Semin Respir Crit Care Med. 2018;39:588–597.CrossRef Hensley MK, Deng JC. Acute on chronic liver failure and immune dysfunction: a mimic of sepsis. Semin Respir Crit Care Med. 2018;39:588–597.CrossRef
7.
Zurück zum Zitat Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.CrossRef Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.CrossRef
8.
Zurück zum Zitat Wang T, Mei Y, Li Z. Research progress on regulatory B cells in systemic lupus erythematosus. Biomed Res Int. 2019;2019:7948687.PubMedPubMedCentral Wang T, Mei Y, Li Z. Research progress on regulatory B cells in systemic lupus erythematosus. Biomed Res Int. 2019;2019:7948687.PubMedPubMedCentral
9.
Zurück zum Zitat Xue W, Yan D, Kan Q. Interleukin-35 as an emerging player in tumor microenvironment. J Cancer. 2019;10:2074–2082.CrossRef Xue W, Yan D, Kan Q. Interleukin-35 as an emerging player in tumor microenvironment. J Cancer. 2019;10:2074–2082.CrossRef
10.
Zurück zum Zitat Zhang J, Zhang Y, Wang Q, et al. Interleukin-35 in immune-related diseases: protection or destruction. Immunology. 2019;157:13–20.CrossRef Zhang J, Zhang Y, Wang Q, et al. Interleukin-35 in immune-related diseases: protection or destruction. Immunology. 2019;157:13–20.CrossRef
11.
Zurück zum Zitat Shao X, Ma J, Jia S, Yang L, Wang W, Jin Z. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection. Front Cell Infect Microbiol. 2017;7:472.CrossRef Shao X, Ma J, Jia S, Yang L, Wang W, Jin Z. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection. Front Cell Infect Microbiol. 2017;7:472.CrossRef
12.
Zurück zum Zitat Liu S, Zhang Q, Shao X, Wang W, Zhang C, Jin Z. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol. 2017;50:87–94.CrossRef Liu S, Zhang Q, Shao X, Wang W, Zhang C, Jin Z. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol. 2017;50:87–94.CrossRef
13.
Zurück zum Zitat Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma. Front Immunol. 2019;10:1032.CrossRef Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma. Front Immunol. 2019;10:1032.CrossRef
14.
Zurück zum Zitat Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J. 2019;16:48.CrossRef Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J. 2019;16:48.CrossRef
15.
Zurück zum Zitat Teng DK, Liu Y, Lv YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol. 2019;70:252–259.CrossRef Teng DK, Liu Y, Lv YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol. 2019;70:252–259.CrossRef
16.
Zurück zum Zitat Li X, Tian L, Dong Y, et al. IL-35 inhibits HBV antigen-specific IFN-gamma-producing CTLs in vitro. Clin Sci (Lond). 2015;129:395–404.CrossRef Li X, Tian L, Dong Y, et al. IL-35 inhibits HBV antigen-specific IFN-gamma-producing CTLs in vitro. Clin Sci (Lond). 2015;129:395–404.CrossRef
17.
Zurück zum Zitat Wang W, Guo H, Li H, et al. Interleukin-35 gene-modified mesenchymal stem cells protect concanavalin A-induced fulminant hepatitis by decreasing the interferon gamma level. Hum Gene Ther. 2018;29:234–241.CrossRef Wang W, Guo H, Li H, et al. Interleukin-35 gene-modified mesenchymal stem cells protect concanavalin A-induced fulminant hepatitis by decreasing the interferon gamma level. Hum Gene Ther. 2018;29:234–241.CrossRef
18.
Zurück zum Zitat Zheng XF, Hu XY, Ma B, et al. Interleukin-35 attenuates D-galactosamine/lipopolysaccharide-induced liver injury via enhancing Interleukin-10 production in Kupffer cells. Front Pharmacol. 2018;9:959.CrossRef Zheng XF, Hu XY, Ma B, et al. Interleukin-35 attenuates D-galactosamine/lipopolysaccharide-induced liver injury via enhancing Interleukin-10 production in Kupffer cells. Front Pharmacol. 2018;9:959.CrossRef
19.
Zurück zum Zitat Morissette MC, Parent J, Milot J. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res. 2007;8:62.CrossRef Morissette MC, Parent J, Milot J. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res. 2007;8:62.CrossRef
20.
Zurück zum Zitat Boegel S, Lower M, Bukur T, Sahin U, Castle JC. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology. 2014;3:e954893.CrossRef Boegel S, Lower M, Bukur T, Sahin U, Castle JC. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology. 2014;3:e954893.CrossRef
21.
Zurück zum Zitat Cheng ST, Yuan D, Liu Y, et al. Interleukin-35 level is elevated in patients with chronic hepatitis B virus infection. Int J Med Sci. 2018;15:188–194.CrossRef Cheng ST, Yuan D, Liu Y, et al. Interleukin-35 level is elevated in patients with chronic hepatitis B virus infection. Int J Med Sci. 2018;15:188–194.CrossRef
22.
Zurück zum Zitat Fu YP, Yi Y, Cai XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767–776.CrossRef Fu YP, Yi Y, Cai XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767–776.CrossRef
23.
Zurück zum Zitat Zhang MX, Gan W, Jing CY, et al. Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection. Cancer Sci. 2018;109:1195–1206.CrossRef Zhang MX, Gan W, Jing CY, et al. Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection. Cancer Sci. 2018;109:1195–1206.CrossRef
24.
Zurück zum Zitat Long J, Guo H, Cui S, et al. IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget. 2016;7:45678–45686.CrossRef Long J, Guo H, Cui S, et al. IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget. 2016;7:45678–45686.CrossRef
25.
Zurück zum Zitat Li T, Huang Y, Liu P, et al. Lower plasma levels of IL-35 in patients with primary biliary cirrhosis. Tohoku J Exp Med. 2018;244:123–131.CrossRef Li T, Huang Y, Liu P, et al. Lower plasma levels of IL-35 in patients with primary biliary cirrhosis. Tohoku J Exp Med. 2018;244:123–131.CrossRef
26.
Zurück zum Zitat Yu X, Guo R, Ming D, et al. The transforming growth factor beta1/Interleukin-31 pathway is upregulated in patients with hepatitis B virus-related acute-on-chronic liver failure and is associated with disease severity and survival. Clin Vaccine Immunol. 2015;22:484–492.CrossRef Yu X, Guo R, Ming D, et al. The transforming growth factor beta1/Interleukin-31 pathway is upregulated in patients with hepatitis B virus-related acute-on-chronic liver failure and is associated with disease severity and survival. Clin Vaccine Immunol. 2015;22:484–492.CrossRef
27.
Zurück zum Zitat Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509–523.CrossRef Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509–523.CrossRef
28.
Zurück zum Zitat Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function. Semin Liver Dis. 2016;36:133–140.CrossRef Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function. Semin Liver Dis. 2016;36:133–140.CrossRef
29.
Zurück zum Zitat Martin-Mateos R, Alvarez-Mon M, Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: it takes two to Tango. Front Immunol. 2019;10:973.CrossRef Martin-Mateos R, Alvarez-Mon M, Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: it takes two to Tango. Front Immunol. 2019;10:973.CrossRef
31.
Zurück zum Zitat Cao D, Xu H, Guo G, et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation. 2013;36:110–120.CrossRef Cao D, Xu H, Guo G, et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation. 2013;36:110–120.CrossRef
32.
Zurück zum Zitat Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010;184:287–295.CrossRef Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010;184:287–295.CrossRef
33.
Zurück zum Zitat Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260.CrossRef Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260.CrossRef
34.
Zurück zum Zitat Yu W, Wang Y, Guo P. Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma. Biomed Pharmacother. 2018;97:535–542.CrossRef Yu W, Wang Y, Guo P. Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma. Biomed Pharmacother. 2018;97:535–542.CrossRef
35.
Zurück zum Zitat Wang HM, Zhang XH, Feng MM, et al. Interleukin-35 suppresses the antitumor activity of T cells in patients with non-small cell lung cancer. Cell Physiol Biochem. 2018;47:2407–2419.CrossRef Wang HM, Zhang XH, Feng MM, et al. Interleukin-35 suppresses the antitumor activity of T cells in patients with non-small cell lung cancer. Cell Physiol Biochem. 2018;47:2407–2419.CrossRef
36.
Zurück zum Zitat Liu MX, Liu QY, Liu Y, et al. Interleukin-35 suppresses antitumor activity of circulating CD8(+) T cells in osteosarcoma patients. Connect Tissue Res. 2019;60:367–375.CrossRef Liu MX, Liu QY, Liu Y, et al. Interleukin-35 suppresses antitumor activity of circulating CD8(+) T cells in osteosarcoma patients. Connect Tissue Res. 2019;60:367–375.CrossRef
Metadaten
Titel
Interleukin-35 Suppresses CD8+ T Cell Activity in Patients with Viral Hepatitis-Induced Acute-on-Chronic Liver Failure
verfasst von
Lanlan Yang
Qian Zhang
Jie Song
Wudong Wang
Zhenjing Jin
Publikationsdatum
24.01.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06077-w

Weitere Artikel der Ausgabe 12/2020

Digestive Diseases and Sciences 12/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.